Evidence map›Paper›PMID 33601309›Full record

ArticleEuropean journal of medicinal chemistry2021

Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.

Sameer Nikhar, Ioannis Siokas, Lisa Schlicher, Seungheon Lee, Mads Gyrd-Hansen, Alexei Degterev, Gregory D Cuny

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. RIPK2: a promising target for cancer treatment.Frontiers in pharmacology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sameer NikharDepartment of Pharmacological and Pharmaceutical Sciences, University of Houston, Health Building 2, Houston, TX, 77204, USA.
Ioannis SiokasDepartment of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA, 02111, USA.
Lisa SchlicherNuffield Department of Medicine, Ludwig Institute for Cancer Research, University of Oxford, Old Road Campus, Roosevelt Drive, OX3 7DQ, UK.
Seungheon LeeDepartment of Pharmacological and Pharmaceutical Sciences, University of Houston, Health Building 2, Houston, TX, 77204, USA.
Mads Gyrd-HansenNuffield Department of Medicine, Ludwig Institute for Cancer Research, University of Oxford, Old Road Campus, Roosevelt Drive, OX3 7DQ, UK.
Alexei DegterevDepartment of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA, 02111, USA. Electronic address: alexei.degterev@tufts.edu.
Gregory D CunyDepartment of Pharmacological and Pharmaceutical Sciences, University of Houston, Health Building 2, Houston, TX, 77204, USA. Electronic address: gdcuny@central.uh.edu.
University of Houston · USTufts University · USUniversity of Oxford · GB

Funding

Targeting RIPK3 in Flu-Associated Lung InjuryR01AI144400 · NIAID · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH, CUNY, GREGORY D · 2019 to 2023
$3.6M
RIP1/3 Kinases as New Targets in Malignant MesotheliomaR01CA190542 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BALACHANDRAN, SIDDHARTH, TESTA, JOSEPH R. · 2015 to 2019
$2.1M
Targeting RIPK3 in Age-Related Inflammation and InjuryR56AG058642 · NIA · TUFTS UNIVERSITY BOSTON · PI BALACHANDRAN, SIDDHARTH, CUNY, GREGORY D · 2018 to 2018
$649k
Dissection of the new pro-inflammatory components of the necrosome complexR21AI124049 · NIAID · TUFTS UNIVERSITY BOSTON · PI DEGTEREV, ALEXEI, GERBER, SCOTT A. · 2017 to 2018
$466k
Targeting RIPK1 and RIPK2 kinases in mouse Experimental Autoimmune EncephalomyelitisR21NS111395 · NINDS · TUFTS UNIVERSITY BOSTON · PI CUNY, GREGORY D, DEGTEREV, ALEXEI · 2019 to 2019
$458k
NCI NIH HHS R01 CA190542NIAID NIH HHS R01 AI144400NIAID NIH HHS R21 AI124049NIA NIH HHS R56 AG058642NINDS NIH HHS R21 NS111395Wellcome Trust 102894/Z/13/Z
6 · The paper itself

Abstract

Receptor interacting protein kinase-2 (RIPK2) is an enzyme involved in the transduction of pro-inflammatory nucleotide-binding oligomerization domain (NOD) cell signaling, a pathway implicated in numerous chronic inflammatory conditions. Herein, a pyrido[2,3-d]pyrimidin-7-one based class of RIPK2 kinase and NOD2 cell signaling inhibitors is described. For example, 33 (e.g. UH15-15) inhibited RIPK2 kinase (IC

Indexed as

Antineoplastic AgentsCell Line, TumorDrug DesignHumansMolecular Docking SimulationNod2 Signaling Adaptor ProteinProtein BindingProtein DomainsProtein Kinase InhibitorsPyridinesPyrimidinonesReceptor-Interacting Protein Serine-Threonine Kinase 2Signal TransductionAntineoplastic AgentsNOD2 protein, humanNod2 Signaling Adaptor ProteinProtein Kinase InhibitorsPyridinesPyrimidinonesReceptor-Interacting Protein Serine-Threonine Kinase 2RIPK2 protein, humanInhibitorKinaseNODNucleotide-binding oligomerization domainPyrido[2,3-d]pyrimidin-7-oneReceptor-interacting protein kinase 2RIPK2

Identifiers

PMID33601309
PMCPMC8009825
OpenAlexW3127053806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.